NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Thursday, February 22, 2024 10:22

Description: Virbac 2013
Release 2.58
Tramvetol 50 mg tablets for dogs
Species: Dogs
Therapeutic indication: Pharmaceuticals: Neurological preparations: Analgesics
Active ingredient: Tramadol hydrochloride
Product:Tramvetol 50 mg tablets for dogs
Product index: Tramvetol 50 mg tablets for dogs
Qualitative and quantitative composition
One tablet contains as active substance(s): Tramadol (as hydrochloride) 43.9 mg. Equivalent to 50 mg of tramadol hydrochloride.
Pharmaceutical form
White to almost white tablets with brown dots with a break line on one side, flat, with rounded edges and a characteristic smell of meat.
Tablets can be divided into 2 equal parts.
Clinical particulars
Target species: Dogs weighing more than 6.25 kg.
Indications for use, specifying the target species: For the reduction of acute and chronic mild soft tissue and musculoskeletal pain.
Contraindications: Do not administer in conjunction with tricyclic antidepressants, monoamine oxidase inhibitors and serotonin reuptake inhibitors.
Do not use in cases of hypersensitivity to tramadol or to any of the excipients. Do not use in animals with epilepsy.
Special warnings for each target species: The analgesic effects of tramadol hydrochloride may be variable. This is thought to be due to individual differences in the metabolism of the drug to the primary active metabolite O-desmethyltramadol. In some dogs (non-responders) this may result in the product failing to provide analgesia. For chronic pain, multimodal analgesia should be considered. Dogs should be monitored regularly by a veterinarian to ensure adequate pain relief. In case of recurrence of pain or insufficient analgesia the analgesic protocol may need to be reconsidered.
Special precautions for use
Special precautions for use in animals: Use with caution in dogs with renal or hepatic impairment. In dogs with hepatic impairment the metabolism of tramadol to the active metabolites may be decreased which may reduce the efficacy of the product. One of the active metabolites of tramadol is renally excreted and therefore in dogs with renal impairment the dosing regimen used may need to be adjusted. Renal and hepatic function should be monitored when using this product. Cessation of long-term analgesic therapy should be done gradually whenever possible.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Tramadol may cause sedation, nausea and dizziness after accidental ingestion, especially by children. To avoid accidental ingestion, particularly by a child, unused tablet parts should be returned to the open blister space and inserted back into the carton and kept in a safe place out of the sight and reach of children. In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or the label to the physician. In case of accidental ingestion by adults: DO NOT DRIVE as sedation may occur. People with known hypersensitivity to tramadol or any of the excipients should avoid contact with the veterinary medicinal product. Wash hands after use.
Adverse reactions (frequency and seriousness): Mild sedation and drowsiness may commonly occur, especially when higher doses are given. Nausea and vomiting have uncommonly been observed in dogs after administration of tramadol. In rare cases hypersensitivity can occur. In cases of hypersensitivity reactions the treatment should be discontinued. In very rare cases tramadol may induce convulsions in dogs with a low seizure threshold.
Use during pregnancy, lactation or lay:
Pregnancy: In laboratory studies conducted on mice and / or rats and rabbits respectively, the use of tramadol did not reveal the existence of teratogenic, foetotoxic, maternotoxic effects. Use only according to the benefit-risk assessment by the responsible veterinarian.
Lactation: In laboratory studies conducted on mice and / or rats and rabbits, respectively, the use of tramadol did not show any negative effects in the peri and post-natal period of offspring. Use only according to the benefit-risk assessment by the responsible veterinarian.
Fertility: In laboratory studies conducted on mice and / or rats and rabbits respectively, the use of tramadol at therapeutic doses did not induce the appearance of unfavorable reactions on reproductive parameters and fertility in the male and female. Use only according to the benefit-risk assessment by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction: Concomitant administration of this product with depressant drugs of the central nervous system may potentiate the effects on C.N.S and respiratory depressant effects. This product can increase the effect of drugs that lower the seizure threshold. Drugs that inhibit (e.g. cimetidine and erythromycin) or induce (e.g. carbamazepine) CYP450 mediated metabolism may have an effect on the analgesic effect of this product. The clinical relevance of this interaction has not yet been definitively studied. The combination with mixed agonist/antagonists (e.g. buprenorphine, butorphanol) and the product is not advisable, because the analgesic effect of a pure agonist may be theoretically reduced in such circumstances.
Amounts to be administered and administration route: For oral use. The recommended dose is 2-4 mg tramadol hydrochloride per kg body weight every 8 hours or as needed based on the intensity of pain. Minimum dosing interval is 6 hours. The recommended maximum daily dose is 16 mg/kg. As the individual response to tramadol is variable and depends partly on the dosage, the age of the patient, individual differences in pain sensitivity and general condition, the optimal dosing regimen should be individually tailored using the above dose and re-treatment interval ranges. The dog should be examined regularly by a veterinarian to assess if additional analgesia is subsequently required. Additional analgesia can be administered by increasing the tramadol dose until the maximum daily dose is reached, and/or by following a multimodal analgesic approach with the addition of other suitable analgesics.
Please note that this dosing table is intended as a guide for dispensing the product at the high end of the dose range: 4 mg/kg bodyweight. It states the number of tablets required to administer 4 mg tramadol hydrochloride per kg bodyweight.
Tablets can be divided into 2 equal parts to ensure accurate dosing.
To divide the tablet, take it with its scored side facing up and press down with your thumbs on both sides of the tablet.
4 mg/kg Bodyweight
Number of tablets
Less than 6.25kg
Not applicable
6.25 kg
12.5 kg
18.75 kg
1 and ½
25 kg
31.25 kg
2 and ½
37.5 kg
50 kg
62.5 kg
Overdose (symptoms, emergency procedures, antidotes), if necessary: In cases of intoxication with tramadol symptoms similar to those observed with other centrally acting analgesics (opioids) are likely to occur. These include in particular miosis, vomiting, cardiovascular collapse, consciousness disorders up to coma, convulsions and respiratory depression up to respiratory arrest. General emergency measures: Maintain a patent airway, support cardiac and respiratory function depending on the symptoms. Inducing vomiting in order to empty the stomach is suitable unless the affected animal is showing reduced consciousness, in which case gastric lavage may be considered. The antidote for respiratory depression is naloxone. However, naloxone may not be useful in all cases of tramadol overdose as it may only partially reverse some of the other effects of tramadol. In case of seizures, administer diazepam.
Pharmacological particulars
Pharmacotherapeutic group: Analgesics, other opioids, tramadol. ATC vet code: QN02AX02.
Pharmacodynamic properties: Tramadol is a centrally acting analgesic agent with a complex mode of action exerted by its 2 enantiomers and primary metabolite, involving opioid, norepinephrine, and serotonin receptors. The (+) enantiomer of tramadol has a low affinity for the μ-opioid receptors, inhibits serotonin uptake and enhances its release. The (-) enantiomer preferentially inhibits norepinephrine reuptake. The metabolite O-desmethyltramadol (M1) has greater affinity for the μ-opioid receptors. Unlike morphine, tramadol does not have depressing effects on respiration for an extensive analgesic dose range. Likewise, it does not affect gastrointestinal motility. The effects on the cardiovascular system tend to be mild. The analgesic potency oftramadol is about 1/10 to 1/6 of that of morphine.
Pharmacokinetic particulars: Tramadol is readily absorbed: After a single oral administration of 4.4 mg tramadol HCL per kg bodyweight, peak plasma concentrations of 65 ng tramadol per mL are achieved within 45 minutes. Food does not significantly affect the absorption of the drug.
Tramadol is metabolized in the liver by cytochrome P450 mediated demethylation followed by conjugation with glucuronic acid. In dogs, lower levels of the active metabolite O-desmethyltramadol are formed compared to humans. Elimination occurs mainly via the kidneys with an elimination half-life of about 0.5-2 hours.
Pharmaceutical particulars
List of excipients: Cellulose, microcrystalline, Starch, pregelatinized, Saccharin sodium, Meat flavour, Silica, colloidal anhydrous, Magnesium stearate
Major incompatibilities: Not applicable.
Shelf life: Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life of divided tablets: 3 days
Special precautions for storage: This veterinary medicinal product does not require any special storage conditions.
Nature and composition of immediate packaging: White PVC/PE/PVDC - aluminium blister.
Pack sizes: Box of 3 blisters of 10 tablets. Box of 10 blisters of 10 tablets. Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
1ère avenue - 2065m - LID
06516 Carros France
Marketing Authorisation Number
Vm 05653/4224
Significant changes
Date of the first authorisation or date of renewal
21 October 2019
Date of revision of the text
Any other information
Legal category
Legal category: POM-V
GTIN description:--